Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma

27 April 2022: Clinical Research

Lei Wang ^1CD* , Lei Wang ^23DEF* , Bo Xiao ^4BC , Mingxuan Cui ^4CDE , Bo Zhang ^4A*

DOI: 10.12659/MSM.934936

Med Sci Monit 2022; 28:e934936

Table 2 Comparison of safety and adverse reactions of the 2 groups (case%).

Group	Hypertension	Hand–foot skin reaction	Diarrhea	Nausea	Fatigue	Frequent urination	Dizziness
S	21 (30.0%)	10 (14.3%)	19 (27.1%)	2 (2.9%)	2 (0.4%)	2 (0.4%)	6 (8.6%)
L	18 (45.0%)^*	4 (10.0%)^*	16 (40.0%)^*	1 (2.5%)	1 (0.0%)	1 (0.0%)	4 (10.0%)
S indicates sorafenib treatment and L indicates lenvatinib treatment. ^* Represents